Subsidy Information and Financing Scheme SDLDolutegravir & Lamivudine Tablet, Dolutegravir 50 mg + Lamivudine 300 mg
Drug Guidance for Subsidy 19/12/2022 Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection The Ministry of Health’s Drug Advisory Committee has recommended: Dolutegravir 50 mg/lamivudi... See all × 19/12/2022 Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection The Ministry of Health’s Drug Advisory Committee has recommended: Dolutegravir 50 mg/lamivudine 300 mg tablet for treating Human Immunodeficiency Virus type 1 (HIV-1) infection in view of acceptable proposal from the company. Funding status RDolutegravir 50 mg/lamivudine 300 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) from 1 February 2023. Information on antiretroviral therapies previously recommended by the Drug Advisory Committee can be found in the Technology Guidance published on 1 September 2020 (Antiretroviral therapies for treating Human Immunodeficiency Virus type 1 (HIV-1) infection)
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet, Dolutegravir 50 mg + Lamivudine 300 mg Changi General Hospital National University Hospital Sengkang General Hospital Singapore General Hospital Tan Tock Seng Hospital